Brief: Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial
02/06/2025 13:35
June 2 (Reuters) - VistaGen Therapeutics Inc VTGN.O: VISTAGEN ON TRACK TO DELIVER TOPLINE DATA FROM FASEDIENOL PALISADE-3 PHASE 3 TRIAL FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER IN THE FOURTH QUARTER OF THIS YEAR VISTAGEN THERAPEUTICS INC - PALISADE-4 PHASE 3 TRIAL RESULTS EXPECTED IN FIRST HALF OF 2026 Source text: ID:nBwNn1f5a Further company coverage: VTGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors